BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 26, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Apremilast: Extension study data

Data from 126 patients enrolled in a 12-week extension study of a 12-week, double-blind, international Phase II trial (CC-10004-PSA-001) showed that twice-daily 20 mg and once-daily 40 mg apremilast improved ACR20 at week 24 by 40% and 39.1%, respectively. The 86 patients who continued twice-daily 20 mg and...

Read the full 217 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >